Illumina (ILMN) shares surged 5.04% during intraday trading on Monday, reflecting investor optimism following the company’s decision to separate its cancer-diagnostics unit, Grail.
The spinoff aims to resolve regulatory challenges and allow Illumina to refocus on its core genomic sequencing operations. This strategic move is expected to simplify the company’s capital allocation and growth priorities, addressing a key concern for investors.
Adding to the positive sentiment, Guggenheim maintained its "Buy" rating on Illumina, reinforcing confidence in the company’s long-term prospects amid the Grail divestiture process.